Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
QIL | Ann: Removal from Official List at close of tradi | 20/09/13 | 0 | 1.4K | |||
|
|||||||
QIL | Ann: Annual Report 2012 | 04/07/13 | 0 | 1.2K | |||
|
|||||||
QIL | Ann: Annual Report 2011 | 04/07/13 | 0 | 1.2K | |||
|
|||||||
QIL | Ann: Annual Report 2010 | 04/07/13 | 0 | 1.0K | |||
|
|||||||
QIL | Ann: Annual Report 2009 | 04/07/13 | 0 | 1.3K | |||
|
|||||||
QIL | Ann: Annual Report 2008 | 04/07/13 | 0 | 994 | |||
|
|||||||
QIL | Ann: Quarterly Report | 03/07/13 | 0 | 960 | |||
|
|||||||
QIL | Ann: Appendix 3B | 12/06/13 | 0 | 1.0K | |||
|
See All Discussions